Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
Stocks · News reference
U.S. stocks were mixed, with the Dow Jones gaining 100 points. Rezolve AI (RZLV) jumped 11.9%, and other stocks such as ALOY and FWRD also rose.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wedbush analyst David Nierengarten initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $35.
BMO Capital analyst David Lebowitz initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Outperform rating and announces Price Target of $37.
Bank of America screened its AI baskets for Buy-rated stocks down over 20% from highs. Micron carries the widest gap to target.
Aktis Oncology (NASDAQ:AKTS) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 98.03 percent increase over losses of $(22.39) per share from
Greenland Mines Ltd. announced the first S-K 1300 technical report for its Sarfartoq neodymium-praseodymium rare earth project in Greenland, achieving a landmark classification of 6.9 million tonnes at Indicated resource status—the first in 15 years of project history. The report models combined open pit and underground mining scenarios (Hybrid case) and includes a strategic partnership with Neo Performance Materials, which gains offtake rights on up to 60% of future production. This regulatory milestone enables the project to support preliminary economic assessment studies, addressing a critical gap in Western rare earth feedstock development.